Development of a tropoelastin-binding MR contrast agent for in vivo imaging of impaired elastogenesis in atherosclerosis by Alkystis Phinikaridou et al.
ORAL PRESENTATION Open Access
Development of a tropoelastin-binding MR
contrast agent for in vivo imaging of impaired
elastogenesis in atherosclerosis
Alkystis Phinikaridou1*, Sara Lacerda1, Marcelo E Andia2,1, Rene Botnar1
From 18th Annual SCMR Scientific Sessions
Nice, France. 4-7 February 2015
Background
Elastin is a primary component of the vessel wall and pre-
sent in all elastic vessels such as the aorta and the pulmon-
ary artery. Elastogenesis begins with the synthesis and
secretion of the soluble precursor tropoelastin that
becomes cross-linked into insoluble elastin. Under normal
conditions cross-linked elastin is the only form of the
molecule present in the vessel wall whereas tropoelastin is
absent. Conversely, under pathological conditions includ-
ing atherosclerosis and aortic aneurysms elastogenesis
resumes and tropoelastin molecules accumulate in the ves-
sel wall. We developed a novel tropoelastin-binding MRI
contrast-agent that would allow 1) specifically bind to tro-
poelastin but not to cross-linked mature elastin to allow
2) detection of pathologic elastogenesis that occurs in
atherosclerosis and 3) minimizing non-specific signal from
endogenously present mature elastin.
Methods
Two tropoelastin-binding peptides (Gd-DOTA)-
VVGSPSAQDEASPLS and K(Gd-DOTA)YPDHVQYTHY
were tested. In vitro binding studies were performed
using Europium-labeled peptides and a DELFIA method.
In vivo MRI of the aortic and brachiocephalic arteries
was performed in atherosclerotic ApoE-/- and control
mice using a 3T Philips Achieva scanner and a single
loop microscopy surface coil. Images were acquired for
up to 1h after intravenous administration of 0.2 mmol/
kg tropoelastin-binding probes. 3D gradient-echo
DE-MRI images were acquired with FOV=30x8x30 mm,
matrix=300, resolution=0.1x0.1mm, slice thick-
ness=0.25mm, TR/TE=27/8ms, TR between subsequent
IR pulses=1000ms, and flip angle=30°. T1 mapping was
performed using a 3D modified Lock-Locker sequence
FOV=22x8x36, matrix=180x171, resolution=0.2x0.2,
slice thickness=0.5mm, TR/TE= 9.2/4.7ms, flip
angle=10°. T1 values were computed on a pixel-by-pixel
basis using an in-house Matlab algorithm.
Results
In vitro binding assays showed high selectivity of the
compounds towards tropoelastin compared to other
proteins and particularly mature elastin (Fig 1). The
VVGS probe achieved best discrimination between tro-
poelastin and mature elastin. Similarly, DE-MRI in vivo
images showed enhancement of the diseased vessel wall
(Fig. 2C-D, G-H; arrows), where tropoelastin is present,
and less or no uptake in control animals (Fig. 2A-2B,
E-F) where tropoelastin is absent. Quantitative analysis
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Figure 1 In vitro binding assays.
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of the vessel wall R1 showed a greater difference in R1
between control and disease vessels walls using the
VVGS based probe (Fig. 2I).
Conclusions
We developed of a new gadolinium-based tropoelastin-
binding contrast agent for imaging atherosclerosis. Both
peptide-based probes showed promising pharmacoki-
netics, specificity and sensitivity for in vivo MRI imaging
diseased brachiocephalic arteries in ApoE-/- mice.
Further development of such contrast agent may allow
for molecular imaging of impaired elastogenesis that
accompany atherosclerotic plaque development and
plaque vulnerability.
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Figure 2 In vivo MRI experiments using the YPDH and VVGS peptides in control and atherosclerotic mice.
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